Website Header with Language Selector and Dropdowns
Image

Ioversol USP Related Compound B


Catalog Number: CL-IOV-008
CAS No.: 104517-96-6
Mol.F: C18H24I3N3O9
Mol.W: 807.1
Inv. Status: Custom Synthesis

Chemical Name: N1,N3-bis(2,3-Dihydroxypropyl)-5-(2-((2-hydroxyethyl)amino)-2-oxoethoxy)-2,4,6-triiodoisophthalamide.

Country of Origin: India

Product Category: Ioversol Impurities


Ioversol USP Related Compound B is identified by CAS No. 104517-96-6 and is chemically known as N1,N3-bis(2,3-Dihydroxypropyl)-5-(2-((2-hydroxyethyl)amino)-2-oxoethoxy)-2,4,6-triiodoisophthalamide.

Ioversol USP Related Compound B is provided with comprehensive characterization data in accordance with regulatory guidelines. It is suitable for use in analytical method development, method validation (AMV), Quality Control (QC) applications for Abbreviated New Drug Applications (ANDA) and commercial production of Ioversol.

Page Keywords: Buy Ioversol USP Related Compound B | Purchase Ioversol USP Related Compound B | Ioversol USP Related Compound B suppliers | Ioversol USP Related Compound B manufacturers | Ioversol USP Related Compound B price | Ioversol USP Related Compound B Importer | Ioversol USP Related Compound B Exporter

Enquiry Now

Personal Details

Product Details

Related Products

CAT No: CL-IOV-001
CAS No: 87771-40-2
Mol Wt: 807.1
Mol F: C18H24I3N3O9
Inv. Status: Custom Synthesis
CAT No: CL-IOV-002
CAS No: 2061892-21-3
Mol Wt: 851.2
Mol F: C20H28I3N3O10
Inv. Status: Custom Synthesis
CAT No: CL-IOV-003
CAS No: 77868-40-7
Mol Wt: 763.1
Mol F: C16H20I3N3O8
Inv. Status: Custom Synthesis
CAT No: CL-IOV-004
CAS No: 2922747-40-6
Mol Wt: 851.2
Mol F: C20H28I3N3O10
Inv. Status: Custom Synthesis
CAT No: CL-IOV-005
CAS No: NA
Mol Wt: 715.7
Mol F: C18H24ClI2N3O9
Inv. Status: Custom Synthesis
CAT No: CL-IOV-006
CAS No: NA
Mol Wt: 851.2
Mol F: C20H28I3N3O10
Inv. Status: Custom Synthesis
CAT No: CL-IOV-007
CAS No: NA
Mol Wt: 851.2
Mol F: C20H28I3N3O10
Inv. Status: Custom Synthesis
Subscribe for news letter:
  

© Cleanchem Laboratories LLP. All Rights Reserved.